UK markets close in 55 minutes

IMV Inc. (IMV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.6200+0.2100 (+4.76%)
As of 10:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.4100
Open4.3400
Bid4.5200 x 1000
Ask4.5500 x 1300
Day's range4.3400 - 4.6800
52-week range1.3500 - 6.8200
Volume35,294
Avg. volume1,859,498
Market cap309.456M
Beta (5Y monthly)2.15
PE ratio (TTM)N/A
EPS (TTM)-0.3390
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum

    IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20th Annual Biotech in Europe Forum held on September 21-24, 2020.

  • Business Wire

    IMV to Participate at Four Upcoming Investor Conferences

    IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the IMV’s executive management team will participate at four upcoming virtual investor conferences in September:

  • IMV INC (IMV) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    IMV INC (IMV) Reports Q2 Loss, Lags Revenue Estimates

    IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more